Resources and free materials for those living with low vision
View ResourcesLive Your Best Life
This site offers up-to-date information and free materials for people living with low vision.
If you are also looking for personal support and contact with others who share your challenges and experiences, please visit our partners at Macular Degeneration Support.
Get SupportPopular Links
-
Low Vision: A Self Help Guide
An evaluation and self-guided workbook designed to help anyone in the intermediate to late stage of vision loss.
-
Caring for the Visually Impaired
This publication is intended to assist all those who are unselfishly committed to caring for visually impaired individuals.
-
Helpful Resources
Self-help tools and resource links to more than 1,600 low vision organizations, services and websites.
Reviews from the Community
-
“These are the most valuable publications a patient can have to navigate and transition into a successful low vision world.”
-
“The booklets and CDs are WONDERFUL! They are going to tremendously help me help my patients.”
-
“Thank you for providing such a wonderful and free service to assist those in need.”
-
"I wonder if you are aware of the great benefit you have provided others with vision problems. You have supplied information and hope in so many areas. Please keep it up."
-
"A mass of well-organized information...fine resource for news, updates and answers to specific queries." (Jean)
Need a Ride?
Our database includes more than 1500 paratransit services in cities across the country. You can search by location or business to find out exactly how to get around safely and comfortably in your area.
Search for TransportationLatest News
-
January 9, 2020
How Do They Come Up With Those Drug Names?
Macugen. Lucentis. Avastin. Eylea. Beovu. All of those are anti-VEGF drugs prescribed for treatment of wet AMD and other conditions involving growth and leakage of new blood vessels in the retina. Those brand names appear in articles and ads, but rarely in eye specialists’ notes and prescription orders. Such names are designed mainly for public […]
-
December 17, 2019
Trials to begin for stem cell-based therapy to treat geographic atrophy
A National Eye Institute (NEI) study will test the safety of a stem cell treatment for the dry (atrophic) form of age-related macular degeneration (AMD). The researchers will take a patient’s own blood cells, and in a lab, convert them into induced pluripotent stem cells (iPSC) capable of becoming any type of cell in the […]
-
December 15, 2019
Cognitive Decline Associated With AMD
Investigators have found significant associations between lessened brain functions and age-related macular degeneration (AMD). 5604 people age 40+ who participated in the 2005-2008 National Health and Nutrition Examination Survey have been found to experience increased memory problems and confusion, seemingly as a result of their AMD. The report was published in the December 2019 issue […]
-
October 20, 2019
Positive Results From RGX-314 Gene Therapy
As reported here in 2017, a drug called RGX-314 is being tested as a one-time sub-retinal injection for wet age-related macular degeneration (wAMD). A preliminary study showed that patients with wAMD had long-term vision stabilization and anatomic improvement following a single treatment with the investigational gene therapy. Now, in a subgroup of patients with the […]
-
October 15, 2019
Port Delivery System Shows Good Phase 2 Trial Results
Genentech has reported end-of-trial results examining the use of their unique alternative to intravitreal injections, the Port Delivery System (PDS). As reported previously here, the PDS is a tiny refillable implant that provides patients affected by wet age-related macular degeneration (AMD) with continuous delivery of Lucentis (ranibizumab) as necessary. Presented by Carl Regillo, MD, at […]
-
October 14, 2019
New Treatment Effective For Treatment of Dry AMD
A Phase 2 study has found that a new drug could be a safe and effective treatment for improving vision in patients with dry age-related macular degeneration (AMD). On October 13, 2019, David Boyer, MD (Retina-Vitreous Associates Medical Group), presented results from a study of risuteganib intravitreal injection to members of the American Academy of […]
-
September 2, 2018
Novel Gene Therapy In Trials for Wet AMD
(Updated 10/12/19) Adverum Biotechnologies, Inc. has announced progress with yet another therapy designed to extend the time between anti-VEGF injections for treatment of wet age-related macular degeneration (wAMD). The company’s Investigational New Drug (IND) application has been approved for a multi-center study of ADVM-022, a novel gene therapy candidate for the treatment of wAMD. “We […]
-
January 18, 2020
The Monster Behind the Door
Speech for PBA Awards BanquetNovember 2, 2012 Dan RobertsFounding DirectorMacular Degeneration Support Thank you for the privilege of speaking to you this evening, and the opportunity to get to know more of the great people of Prevent Blindness America. I’ve long admired the work of this organization and have referred many of our low vision […]
-
January 17, 2020
What’s So Funny About Low Vision?
by Dan Roberts What’s so funny about low vision? Nothing really, but some humor can come from living with it. You know, those gaffes and missteps which may not be funny to anyone who hasn’t lived with visual impairment, but which can make us grin when we realize we’re not the only ones who commit […]
-
January 17, 2020
Riding the Wave of Evolving Technology
(Featuring “Sarah’s Day”) by Dan Roberts As an unabashed gadget geek, I have followed the development of low vision technology since my diagnosis in 1994. The first fifteen of those years offered a number of optical and non-optical devices to help our low vision community get by, and we have hungrily consumed each and every […]